Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Clinical  ·  Weekly Digest 14 June to 20 June 2025
IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan initiated in patients with pretreated metastatic castration-resistant prostate cancer

Weekly Digest – June 2025 Weekly Digest – June 2025 18 June 2025: IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan initiated in patients with pretreated metastatic castration-resistant prostate cancer The IDeate-Prostate01 Phase 3 trial has begun, evaluating Ifinatamab deruxtecan (I-DXd) […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 14 June to 20 June 2025
Debiopharm’s ADC research gains momentum with launch of first-in-human trial assessing Debio 1562M in acute myeloid leukemia patients

Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: Debiopharm’s ADC research gains momentum with launch of first-in-human trial assessing Debio 1562M in acute myeloid leukemia patients Debiopharm has dosed the first patient in a Phase […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 07 June to 13 June 2025
Kelun-Biotech announces breakthrough therapy designation granted for Sacituzumab tirumotecan (Sac-TMT) in combination with Tagitanlimab in China for certain types of Non-Small Cell Lung Cancer

Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Kelun-Biotech announces breakthrough therapy designation granted for Sacituzumab tirumotecan (Sac-TMT) in combination with Tagitanlimab in China for certain types of Non-Small Cell Lung Cancer Sichuan Kelun-Biotech’s TROP2-directed […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 07 June to 13 June 2025
DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer

Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer Daiichi Sankyo and AstraZeneca have initiated […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 07 June to 13 June 2025
Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services

Weekly Digest – June 2025 Weekly Digest – June 2025 11 June 2025: Simtra BioPharma solutions and MilliporeSigma announce strategic alliance for antibody drug conjugates drug substance and drug product manufacturing services Simtra BioPharma Solutions and MilliporeSigma (Merck KGaA’s Life […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 07 June to 13 June 2025
Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates

Weekly Digest – June 2025 Weekly Digest – June 2025 10 June 2025: Medicovestor and Sanyou Biopharmaceuticals forge strategic partnership to develop first-in-class chemoimmunotherapy antibody-drug conjugates  Medicovestor and Sanyou Biopharmaceuticals have formed a strategic partnership to co-develop first-in-class chemoimmunotherapy antibody-drug […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 07 June to 13 June 2025
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMine Enabling Technologies

Weekly Digest – June 2025 Weekly Digest – June 2025 06 June 2025: OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMine Enabling Technologies OBI Pharma and TegMine Therapeutics have entered a Master Services Agreement to collaborate […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 07 June to 13 June 2025
SK plasma enters ADC cancer drug development with AIMEDBIO partnership

Weekly Digest – June 2025 Weekly Digest – June 2025 09 June 2025: SK plasma enters ADC cancer drug development with AIMEDBIO partnership  SK plasma has partnered with AIMEDBIO to co-develop an antibody-drug conjugate (ADC) targeting ROR1, marking SK plasma […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 31 May to 06 June 2025
European Commission approves ADCETRIS® (Brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV hodgkin lymphoma in combination with ECADD

Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: European Commission approves ADCETRIS (Brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV hodgkin lymphoma in combination with ECADD Takeda’s ADCETRIS-based regimen BrECADD […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 31 May to 06 June 2025
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Weekly Digest – June 2025 Weekly Digest – June 2025 02 June 2025: Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting Eli Lilly’s FRα-targeting ADC (LY4170156) […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous424344454647484950Next ›Last »
Page 46 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id